Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M85.0Revenue $M0.3Net Margin (%)-10,721.2Z-Score-15.3
Enterprise Value $M74.7EPS $-0.5Operating Margin %-10,984.4F-Score2
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-10,721.2Higher ROA y-yN
Price/Book7.010-y EBITDA Growth Rate %0Quick Ratio2.9Cash flow > EarningsY
Price/Sales2235-y EBITDA Growth Rate %0Current Ratio3.3Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-139.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-258.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M91.5ROI % (ttm)-121.7Gross Margin Increase y-yN

Gurus Latest Trades with CVM

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

CVM is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CVM: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KERSTEN GEERT RCEO 2014-10-13Buy14,999$0.7727.27 view
KERSTEN GEERT RCEO 2013-12-30Buy300,000$0.663.33 view
KERSTEN GEERT RChief Executive 2013-10-09Buy8,400$0.7924.05 view
YOUNG PETER RDirector 2013-06-19Buy25,000$0.24308.33 view
KERSTEN GEERT RChief Executive 2013-06-14Buy145,120$0.24308.33 view
KERSTEN GEERT RCEO 2013-05-20Buy40,000$0.25292 view
KERSTEN GEERT RCEO 2013-05-02Buy118,700$0.27262.96 view
PRICHEP PATRICIA BSenior Vice President 2013-03-27Buy25,000$0.22345.45 view
YOUNG PETER RDirector 2013-03-27Buy25,000$0.23326.09 view
KERSTEN GEERT RCEO 2013-03-26Buy348,125$0.21366.67 view

Press Releases about CVM :

    Quarterly/Annual Reports about CVM:

    News about CVM:

    Articles On GuruFocus.com
    Updated Coverage Report Focuses on CEL-SCI Corporation Jan 12 2015 
    Coverage Initiation Report Focuses on CEL-SCI Corporation Oct 15 2014 
    CELSCISci Corp Reports Operating Results (10-Q) Feb 09 2011 
    CELSCISci Corp Reports Operating Results (10-Q) Aug 16 2010 
    CELSCISci Corp Reports Operating Results (10-Q) May 17 2010 
    CELSCISci Corp Reports Operating Results (10-Q) Feb 12 2010 
    CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
    CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
    CELSCISci Corp Reports Operating Results (10-Q/A) Jan 29 2010 
    CELSCISci Corp Reports Operating Results (10-K) Jan 13 2010 

    More From Other Websites
    NEW STORY UK's Aintree University Hospital Joins CEL-SCI's Phase III Head and Neck Cancer Trial Apr 13 2015
    UK’s Aintree University Hospital Joins CEL-SCI’s Phase III Head and Neck Cancer Trial Apr 13 2015
    UK’s Aintree University Hospital Joins CEL-SCI’s Phase III Head and Neck Cancer Trial Apr 13 2015
    CEL SCI CORP Files SEC form 8-K, Other Events Apr 02 2015
    NEW STORY CEL-SCI Reports 3rd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase... Apr 01 2015
    CEL-SCI Reports 3rd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head... Apr 01 2015
    CEL SCI CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year Mar 18 2015
    Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity Mar 12 2015
    CEL-SCI Corp (CVM) Falls: Stock Goes Down 7% - Tale of the Tape Mar 09 2015
    CEL-SCI Corporation (CVM) in Focus: Stock Jumps 5.6% - Tale of the Tape Mar 04 2015
    NEW STORY CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries Mar 03 2015
    NEW STORY CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase... Mar 03 2015
    CEL-SCI Reports 2nd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head... Mar 03 2015
    Coverage initiated on CEL-SCI Corp by Dawson James Mar 02 2015
    Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products... Mar 02 2015
    NEW STORY CEL-SCI to Participate in Ascendiant's Quarterly Management Discussion Series Today,... Feb 27 2015
    CEL-SCI Completes Key Milestone with Clearance to Conduct Phase III Trial in 21 Countries Feb 27 2015
    CEL-SCI Corporation (NYSE MKT: CVM), Arguably the Most Undervalued Phase III Biotech, is Featured in... Feb 27 2015
    CEL-SCI Corp.'s CEO Geert Kersten Interviewed by The Life Sciences Report Feb 23 2015
    FinancialBuzz.com Exclusive Interview With CEL-SCI CEO Geert Kersten From the Floor of the NYSE Feb 23 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK